{"id":6919,"date":"2026-08-12T13:06:19","date_gmt":"2026-08-12T13:06:19","guid":{"rendered":"https:\/\/www.paytmmoney.com\/blog\/?p=6919"},"modified":"2026-08-12T13:08:10","modified_gmt":"2026-08-12T13:08:10","slug":"credent-connect-n-care-ipo-review","status":"publish","type":"post","link":"https:\/\/www.paytmmoney.com\/blog\/credent-connect-n-care-ipo-review\/","title":{"rendered":"Credent Connect N Care IPO Review: Key Details, Company Overview & Financials"},"content":{"rendered":"

Credent Connect IPO is a book-built issue of \u20b993.90 crores, comprising an entirely fresh issue of 0.50 crore shares aggregating to \u20b993.90 crore. <\/span>The IPO will open for subscription on Aug 13, 2026 and close on Aug 17, 2026. The allotment is expected to be finalized on Aug 18, 2026, with the shares proposed to be listed on the NSE SME platform on Aug 20, 2026.<\/span><\/p>\n

The issue has a price band of \u20b9179 to \u20b9189 per share, with a lot size of 600 shares. The minimum retail investment is \u20b92,26,800 (1,200 shares), based on the upper price band. For HNI investors, the minimum application is 3 lots (1,800 shares), requiring an investment of \u20b93,40,200. <\/span>Hem Securities Ltd. is the book running lead manager, while Kfin Technologies Ltd. is the registrar to the issue.<\/span><\/p>\n

For detailed information on the company’s business, financials, risk factors, and the proposed utilisation of proceeds, investors should refer to the Credent Connect IPO<\/span> Red Herring Prospectus (RHP)<\/span> <\/span><\/a>before making an investment decision.<\/span><\/p>\n

Company Overview<\/b><\/h2>\n

Incorporated in June 2015 as Credent Cold Chain Logistics Private Limited, Credent Connect N Care Limited is an integrated healthcare services and logistics company providing technology-driven operational, workforce and supply chain solutions to healthcare institutions across India. The company follows a B2B model and serves diagnostic laboratories, IVD companies, pharmaceutical companies, hospitals, clinics and other healthcare businesses.<\/span><\/p>\n

Its service portfolio covers home sample collection through trained phlebotomists, laboratory and healthcare manpower solutions, diagnostic and paramedical services, healthcare logistics, operations and supply chain management, corporate wellness programs, and technology-enabled courier aggregation through its C3 Post platform. The company also provides temperature-controlled and time-sensitive transportation for diagnostic samples, medical supplies, reagents and other healthcare consignments.<\/span><\/p>\n

Credent Connect N Care has a pan-India presence supported by warehouses, branch offices, commercial vehicles, field personnel and technology systems for tracking, workforce management and operational coordination. Its corporate wellness business operates under the \u201cC3 Wellness\u201d brand and provides health camps, vaccination programs, preventive health check-ups, radiology and diagnostic services, and on-ground healthcare manpower.<\/span><\/p>\n

As of March 31, 2026, the company had a workforce of 6,338 employees, including 4,052 payroll and 2,286 contractual employees. <\/span>The company has strengthened its operations through acquisitions of Credent Healthcare Private Limited, Credent Team Private Limited and Alltrak Technologies Private Limited. Its capabilities are supported by ISO 9001:2015 and ISO 15189:2022 certifications, along with an experienced promoter-led management team with expertise in healthcare logistics and operations.<\/span><\/p>\n

IPO Details<\/b><\/h2>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Particulars<\/th>\nDetails<\/th>\n<\/tr>\n<\/thead>\n
IPO Date<\/td>\n13 to 17 Aug, 2026<\/td>\n<\/tr>\n
Allotment<\/td>\nTue, Aug 18, 2026<\/td>\n<\/tr>\n
Listing Date<\/td>\nThu, Aug 20, 2026<\/td>\n<\/tr>\n
Face Value<\/td>\n\u20b910 per share<\/td>\n<\/tr>\n
Price Band<\/td>\n\u20b9179 to \u20b9189 per share<\/td>\n<\/tr>\n
Lot Size<\/td>\n600 Shares<\/td>\n<\/tr>\n
Issue Type<\/td>\nBook Building IPO<\/td>\n<\/tr>\n
Sale Type<\/td>\nFresh capital only<\/td>\n<\/tr>\n
Total Issue Size<\/td>\n49,68,000 shares (agg. up to \u20b994 Cr)<\/td>\n<\/tr>\n
Reserved for Market Maker<\/td>\n2,52,000 shares (agg. up to \u20b95 Cr)<\/td>\n<\/tr>\n
Fresh Issue (Ex Market Maker)<\/td>\n47,16,000 shares (agg. up to \u20b989 Cr)<\/td>\n<\/tr>\n
Shareholding Pre-Issue<\/td>\n1,32,54,900 shares<\/td>\n<\/tr>\n
Shareholding Post-Issue<\/td>\n1,82,22,900 shares<\/td>\n<\/tr>\n
Listing Exchange<\/td>\nNSE SME<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

(Compiled from RHP and market updates)<\/span><\/span><\/i><\/p>\n

Industry Context<\/b><\/h2>\n
    \n
  • India\u2019s diagnostic laboratory market grew from USD 11.07 billion in FY 2021 to USD 16.50 billion in FY 2025, registering a CAGR of 10.5%, driven by preventive healthcare, lifestyle diseases and wider access in Tier-2 and Tier-3 cities.<\/span><\/li>\n
  • Major players such as Dr. Lal PathLabs, Metropolis Healthcare, Thyrocare Technologies and others are expanding through central labs, collection centres and technology-enabled networks, improving accessibility and service efficiency.<\/span><\/li>\n
  • Home sample collection, digital bookings, LIS, automation, AI-enabled testing, molecular diagnostics and genomics are increasingly improving convenience, testing capacity and operational efficiency.<\/span><\/li>\n
  • The diagnostic laboratory market is expected to increase from USD 16.50 billion in FY 2025E to USD 31.50 billion by FY 2030E, with growth supported by preventive care, chronic disease screening and advanced testing.<\/span><\/li>\n
  • Pharmaceutical logistics requires controlled handling of sensitive products. Cold rooms operate at 2\u22128\u00b0C, deep freezers at \u221220\u00b0C or below, and controlled ambient zones at 15\u221225\u00b0C, supported by monitoring and validated storage systems.<\/span><\/li>\n<\/ul>\n

    Business Strengths<\/b><\/h2>\n
      \n
    • Credent Connect provides multiple healthcare-related services under one platform, including healthcare logistics, diagnostic support, manpower solutions, sample collection and operational assistance. This integrated model enables healthcare institutions to access several complementary services through a single service provider.<\/span><\/li>\n
    • The company has established a broad presence across India and caters to a wide range of B2B customers, including diagnostic laboratories, IVD companies, pharmaceutical businesses, hospitals, clinics and other healthcare enterprises. Its distributed operations support service delivery across multiple locations.<\/span><\/li>\n
    • Credent Connect manages the movement of diagnostic samples, medical supplies, reagents and other healthcare consignments. Its logistics capabilities include temperature-controlled transportation and time-sensitive deliveries, which are particularly important for healthcare products and diagnostic materials requiring controlled handling.<\/span><\/li>\n
    • The company uses technology to improve operational coordination, workforce management, tracking and service execution. Platforms such as C3 Post and C3 HRMS support activities including courier aggregation, employee management and real-time operational monitoring.<\/span><\/li>\n
    • Beyond logistics, the company operates across diagnostic services, healthcare manpower, home sample collection, paramedical support and corporate wellness. This diversified offering allows it to address different operational requirements of healthcare institutions and reduces reliance on a single service category.<\/span><\/li>\n
    • The company has expanded its capabilities through acquisitions such as Credent Healthcare Private Limited, Credent Team Private Limited and Alltrak Technologies Private Limited. These acquisitions have helped broaden its service capabilities and strengthen its presence across healthcare operations and logistics.<\/span><\/li>\n<\/ul>\n

      Business Risks<\/b><\/h2>\n
        \n
      • The company\u2019s business is closely linked to the performance and spending patterns of the healthcare industry. Any slowdown in diagnostic, pharmaceutical or hospital activity could affect demand for its services.<\/span><\/li>\n
      • The transportation of diagnostic samples, medical supplies and temperature-sensitive consignments requires strict handling and monitoring. Any breakdown in cold-chain infrastructure, delays or improper handling could result in losses, damaged consignments and reputational concerns.<\/span><\/li>\n
      • Several of the company\u2019s services rely on trained phlebotomists, healthcare professionals, logistics personnel and other field employees. Difficulty in recruiting, training or retaining suitable personnel could affect its ability to maintain service standards.<\/span><\/li>\n
      • The company relies on technology platforms for workforce management, tracking, courier aggregation and operational coordination. System failures, data breaches, cyberattacks or technology disruptions could interrupt operations and compromise sensitive information.<\/span><\/li>\n
      • Credent Connect operates in multiple segments where it faces competition from established healthcare service providers, diagnostic companies, logistics operators and specialised manpower agencies. Competitive pricing or stronger service offerings from rivals could put pressure on margins and market share.<\/span><\/li>\n
      • The company has expanded through acquisitions, which can involve challenges related to integrating employees, systems, processes and operations. Failure to achieve expected synergies from these acquisitions could affect business performance.<\/span><\/li>\n<\/ul>\n

        Financial Performance<\/b><\/h2>\n

        Credent Connect N Care Limited- Financials (\u20b9 in lakh)<\/b><\/h3>\n
        \n\n\n\n\n\n\n\n\n\n\n\n
        Particulars<\/th>\nFY 2025-26<\/th>\nFY 2024-25<\/th>\nFY 2023-24<\/th>\n<\/tr>\n<\/thead>\n
        Revenue from Operations<\/td>\n21,416.18<\/td>\n7,794.26<\/td>\n7,573.32<\/td>\n<\/tr>\n
        Net Worth<\/td>\n4,379.07<\/td>\n1,590.27<\/td>\n1,365.60<\/td>\n<\/tr>\n
        EBITDA<\/td>\n2,846.36<\/td>\n499.48<\/td>\n429.63<\/td>\n<\/tr>\n
        EBITDA Margin (%)<\/td>\n13.29%<\/td>\n6.41%<\/td>\n5.67%<\/td>\n<\/tr>\n
        Profit After Tax (PAT)<\/td>\n1,844.78<\/td>\n224.67<\/td>\n266.44<\/td>\n<\/tr>\n
        Return on Capital Employed (%)<\/td>\n61.81%<\/td>\n16.96%<\/td>\n20.00%<\/td>\n<\/tr>\n
        Return on Equity (%)<\/td>\n40.00%<\/td>\n15.20%<\/td>\n21.62%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

        <\/p>\n

        \u2190 Swipe horizontally to view full table \u2192<\/div>\n